Bohm M, Anker S, Mahfoud F, Lauder L, et al. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J 2022 Dec 7:ehac693. doi: 10.1093.
PMID: 36478225